Hinge Bio’s GEM-DIMER™ platform was developed to create next-generation therapeutics for difficult to treat diseases.
Currently in Phase I clinical trials, HB2198 is designed to become the new standard of care in the treatment of B cell-mediated diseases such as lupus.
Hinge Bio is a proven team of drug developers and biotech leaders united by a commitment to improving the lives of individuals with immune-mediated diseases and cancer.